Aldeyra Therapeutics (ALDX) Price & Analysis

Compare

1,678 Followers

ALDX Stock Chart & Stats

$4.95

-$0.07(-1.37%)

At close: Jan 08 4:00 PM EST

$4.95

-$0.07(-1.37%)

Day’s Range― - ―

52-Week Range$1.14 - $7.20

Previous CloseN/A

Volume102.94K

Average Volume (3M)772.10K

Market Cap

$282.77M

Enterprise ValueN/A

Total Cash (Recent Filing)$75.30M

Total Debt (Recent Filing)$15.54M

Price to Earnings (P/E)―

Beta2.28

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding60,162,773

10 Day Avg. Volume974,607

30 Day Avg. Volume772,095

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)4.18

Price to Sales (P/S)0.00

P/FCF Ratio-6.87

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.67

Price Target Upside75.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Product DevelopmentThe next-generation RASP modulator ADX-248 is being expanded to include CNS neuroinflammatory diseases, based on preclinical progress in Parkinson's models and amyotrophic lateral sclerosis.

Regulatory ApprovalApproval is likely as the FDA recognizes Reproxalap as a differentiated DED drug with a disease-modifying mechanism resulting in treatment effects seen within minutes.

Strategic PartnershipsA potential commercial relationship with AbbVie seems a significant positive for the prospects of reproxalap as the AbbVie partnership is likely needed for Reproxalap to gain timely patient access and reimbursement.

Bears Say

Financial ConcernsThe cash position could become limiting as Aldeyra shifts to exploring systemic applications of RASP scavenging.

Aldeyra Therapeutics News

Aldeyra expands RASP platform

Aldeyra (ALDX) announced at a research and development webcast the expansion of the RASP platform to include programs...

27d ago

ALDX

Aldeyra Therapeutics: Promising Advancements and Strategic Positioning Drive Buy Rating

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ALDX stock, giving a Buy rating on...

23d ago

ALDX

Promising Developments and Regulatory Progress Drive Buy Rating for Aldeyra Therapeutics

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Aldeyra Therapeutics, with a...

26d ago

ALDX

Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On November 13, 2025, Aldeyra Therapeutics announced updates during...

27d ago

ALDX

Aldeyra ADX-629 achieves statistically significant improvement in liver function

Aldeyra (ALDX) announced achievement of statistically significant improvement in liver function in patients treated with ADX-629, an investigational...

1M ago

ALDX

Aldeyra Therapeutics Reports Positive Phase 2 Trial Results

Aldeyra Therapeutics ( ($ALDX) ) has provided an update. On October 28, 2025, Aldeyra Therapeutics announced positive results...

1M ago

ALDX

Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial

Aldeyra Therapeutics (($ALDX)) announced an update on their ongoing clinical study. Study Overview: Aldeyra Therapeutics is conducting a...

1M ago

ALDX

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics

Clara Dong, an analyst from Jefferies, maintained the Buy rating on Aldeyra Therapeutics. The associated price target is...

2M ago

ALDX

Aldeyra price target raised to $7 from $6 at Jefferies

Jefferies analyst Clara Dong raised the firm’s price target on Aldeyra (ALDX) to $7 from $6 and keeps...

2M ago

ABBV

ALDX

Aldeyra receives orphan designation from EMA for ADX-2191

Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of...

3M ago

ALDX

Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On August 19, 2025, Aldeyra Therapeutics announced that the...

4M ago

ALDX

Aldeyra granted fast track designation for ADX-2191 by FDA

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis...

4M ago

ALDX

Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating

Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Aldeyra Therapeutics and keeping the price target...

4M ago

ALDX

Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on ALDX stock, giving a Buy rating on...

4M ago

ALDX

ALDX FAQ

What was Aldeyra Therapeutics’s price range in the past 12 months?

Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.

What is Aldeyra Therapeutics’s market cap?

Aldeyra Therapeutics’s market cap is $282.77M.

When is Aldeyra Therapeutics’s upcoming earnings report date?

Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 141 days.

How were Aldeyra Therapeutics’s earnings last quarter?

Currently, no data Available

Is Aldeyra Therapeutics overvalued?

According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics does not currently pay dividends.

What is Aldeyra Therapeutics’s EPS estimate?

Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 60,162,773 shares outstanding.

What happened to Aldeyra Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aldeyra Therapeutics?

Currently, no hedge funds are holding shares in ALDX

Aldeyra Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-64.31%

Trailing 12-Months

Asset Growth

-33.68%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company engaged in the development of innovative therapies for immune-mediated diseases. The company's core focus is on the identification and development of drugs that alleviate inflammation and other related conditions by targeting reactive aldehyde species, which are implicated in numerous diseases. Aldeyra's product pipeline includes treatments for conditions such as dry eye disease, allergic conjunctivitis, and non-infectious anterior uveitis.

Aldeyra Therapeutics (ALDX) Earnings & Revenues

Historic Earnings Reports

ALDX Stock 12 Month Forecast

Average Price Target

$8.67

▲(75.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.44923076923077,5.828461538461538,6.207692307692308,6.586923076923077,6.966153846153846,7.345384615384615,7.724615384615385,8.103846153846154,8.483076923076922,8.862307692307692,9.241538461538461,9.62076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.346923076923077,5.623846153846154,5.900769230769231,6.177692307692308,6.454615384615384,6.731538461538461,7.008461538461539,7.285384615384615,7.562307692307693,7.839230769230769,8.116153846153846,8.393076923076922,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.218461538461539,5.366923076923078,5.515384615384615,5.663846153846154,5.812307692307693,5.960769230769231,6.10923076923077,6.257692307692308,6.406153846153846,6.554615384615385,6.703076923076923,6.851538461538462,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.71,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >